cAMP-specific 3',5'-cyclic phosphodiesterase 4C isoform 2 (PDE4C2) (PDE4C2)

cAMP-specific 3',5'-cyclic phosphodiesterase 4C (PDE4C) is an enzyme that plays a critical role in signal transduction by catalyzing the hydrolysis of the second messenger cyclic adenosine monophosphate (cAMP) [1]. The PDE4C2 isoform is a specific long-form splice variant of the PDE4C gene, distinguished by its unique N-terminal domain that facilitates specific subcellular targeting and protein-protein interactions [3]. By maintaining cAMP homeostasis, PDE4C2 influences various physiological processes, including the regulation of inflammatory mediators and the modulation of smooth muscle tone [2]. Although PDE4C is less prominently featured in drug discovery compared to the PDE4B and PDE4D isoforms, it is inhibited by clinically approved pan-PDE4 inhibitors such as roflumilast and apremilast [4]. These therapeutic agents work by elevating intracellular cAMP levels, which subsequently activates protein kinase A and suppresses the production of pro-inflammatory cytokines like TNF-alpha [5]. However, the clinical utility of targeting PDE4 isoforms is often limited by class-related side effects, most notably gastrointestinal distress and nausea, which are thought to result from PDE4 inhibition in the central nervous system and the gut [6].

Other names

PDE4CDPDE1Phosphodiesterase 4C isoform 2cAMP-specific 3',5'-cyclic phosphodiesterase 4C

Competitive inhibition of the catalytic site of PDE4, preventing the hydrolysis of cAMP to 5'-AMP, thereby increasing intracellular cAMP levels and activating protein kinase A (PKA) and Epac pathways.